MS
BTAI icon

Maven Securities’s BioXcel Therapeutics BTAI Stock Holding History

Maven Securities’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,500
Closed -$8.61M – 595
2020
Q3 		$8.61M Buy
+12,500
New +$9.39M 0.71% 25

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Maven Securities's BTAI Position: Q4 2020 in Review

Maven Securities sold out of BioXcel Therapeutics (BTAI) in Q4 2020, closing a stake of 12,500 shares — an estimated $8.61M sold.

Maven Securities first reported a position in BTAI in Q3 2020 and held it in 1 quarter. The position peaked at $8.61M in Q3 2020. 117 funds tracked by Wall St. Rank hold BTAI as of Q4 2020.

  • Maven Securities reported no remaining BioXcel Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Maven Securities sold 12,500 BioXcel Therapeutics shares in Q4 2020, an estimated $8.61M.
  • Maven Securities first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 1 quarter.
  • Maven Securities's BioXcel Therapeutics position peaked at $8.61M in Q3 2020.
  • 117 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2020.

Based on Maven Securities's 13F filing for Q4 2020, filed 12 Feb 2021.